NFKB1 and neoplasm: NFκB will be assayed as a tumor activation marker in a trial of the combination of chemotherapy and an anti-hypertensive, aiming to suppress myeloid-derived suppressor cells (MDSCs) in patients with resectable gastric or gastroesophageal junction adenocarcinoma (NCT05709574).